When patients with Oncocytomas accurately can be identified pre-operatively, unnecessary surgery/treatment can be avoided.
Within Stockholm´s County and at Karolinska University hospital 250/ 120 patients are treated for suspected Renal Cell Carcinoma (RCC) annually. In a large majority of these cases the masses are post-operative found to be malignant and the patient benefit from the treatment. However the number of benign tumours, today often pre-operatively miss-classified as probable malignant is not negligible (5-20 percent). Oncocytoma is one of the most commonly occurring benign renal tumours and is today difficult to differentiate from RCC pre-operatively. This results in unnecessary and expensive treatment of a number of patients not benefitting from the procedure. The cost for a surgical resection for T1 A-B suspected RCC is estimated to 90 000-100 000 SEK.
Oncocytomas are unique tumour type in the ultrastactural level as these tumours are composed of cells with numerous densely packed mitochondria. A known mitochondrial imaging agent 99mTc-Sestamibi, has recently been used in studies including only a small number of patients with suspected RCC but with very promising results.
In this prospective study we will evaluate the diagnostic accuracy of gamma camera investigation with 99mTc-Sestamibi SPECT/CT in 180 patients with suspected RCC. Quantitative evaluation will be made with software developed by Hermes Medical Solutions and correlated to histopathology.
When patients with Oncocytomas accurately can be identified pre-operatively, unnecessary surgery/treatment can be avoided. In the long term this will result in avoiding suffering for patient not benefitting treatment, releasing treatment capacity to true RCC-patients. Unnecessary surgery can thus be avoided and costs can be reduced both for the health care system and the society as whole.
MORE ABOUT THE PROJECT
Project leader Rimma Axelsson, Karolinska Universitetssjukhuset firstname.lastname@example.org
Funding from SWElife 1 898 665 SEK
Call for proposal SWElife spring 2015 call, for proposals for collaborative innovation projects within non-communicable diseases
About the project at Vinnova (in Swedish)